Q2 EPS Forecast for Blueprint Medicines Lifted by Analyst

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Investment analysts at Zacks Research increased their Q2 2025 earnings per share (EPS) estimates for Blueprint Medicines in a report issued on Wednesday, May 21st. Zacks Research analyst A. Chakraborty now forecasts that the biotechnology company will post earnings per share of ($0.59) for the quarter, up from their prior forecast of ($0.64). The consensus estimate for Blueprint Medicines' current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Blueprint Medicines' Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.12 EPS, FY2026 earnings at $0.28 EPS and FY2027 earnings at $2.79 EPS.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The firm had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. During the same quarter in the previous year, the company posted $1.40 earnings per share. The business's revenue for the quarter was up 55.5% compared to the same quarter last year.

BPMC has been the subject of several other research reports. HC Wainwright reissued a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, May 2nd. Wolfe Research began coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They set an "outperform" rating for the company. Needham & Company LLC cut their price objective on Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a report on Monday, April 28th. Jefferies Financial Group began coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They issued a "buy" rating and a $135.00 target price on the stock. Finally, Wedbush reiterated an "outperform" rating and set a $128.00 target price on shares of Blueprint Medicines in a research report on Thursday, May 1st. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $126.56.

Blueprint Medicines Price Performance

Shares of BPMC stock traded down $0.61 during mid-day trading on Monday, reaching $102.45. The company's stock had a trading volume of 271,364 shares, compared to its average volume of 986,399. The firm's 50-day moving average is $91.51 and its two-hundred day moving average is $94.65. The company has a market cap of $6.62 billion, a P/E ratio of -94.43 and a beta of 0.83. Blueprint Medicines has a 1-year low of $73.04 and a 1-year high of $121.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85.

Hedge Funds Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently made changes to their positions in BPMC. Intrust Bank NA lifted its holdings in Blueprint Medicines by 3.4% during the first quarter. Intrust Bank NA now owns 3,557 shares of the biotechnology company's stock worth $315,000 after acquiring an additional 118 shares in the last quarter. Fifth Third Bancorp raised its position in shares of Blueprint Medicines by 4.7% during the first quarter. Fifth Third Bancorp now owns 3,221 shares of the biotechnology company's stock worth $285,000 after purchasing an additional 146 shares during the period. Covestor Ltd lifted its holdings in shares of Blueprint Medicines by 15.9% during the 1st quarter. Covestor Ltd now owns 1,128 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 155 shares in the last quarter. Torray Investment Partners LLC grew its position in shares of Blueprint Medicines by 1.1% in the 1st quarter. Torray Investment Partners LLC now owns 16,679 shares of the biotechnology company's stock valued at $1,476,000 after purchasing an additional 180 shares during the period. Finally, Headlands Technologies LLC increased its stake in Blueprint Medicines by 25.0% during the 1st quarter. Headlands Technologies LLC now owns 936 shares of the biotechnology company's stock worth $83,000 after purchasing an additional 187 shares in the last quarter.

Insider Buying and Selling

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 5,000 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $101.14, for a total transaction of $505,700.00. Following the transaction, the director now owns 146,630 shares in the company, valued at approximately $14,830,158.20. This trade represents a 3.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares in the company, valued at $1,692,167.40. This represents a 14.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,777 shares of company stock valued at $1,762,190 over the last ninety days. Insiders own 4.21% of the company's stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.